Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer

• Published in: Breast cancer research : BCR Vol. 26; no. 1; pp. 1 - 15
• Main Authors: Du, Jiaqun, Liu, Xiaobang, Sun, Junpeng, Wu, Qian, Hu, Yu, Shi, Huan, Zheng, Li, Liu, Ying, Wu, Chao, Gao, Yu
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 12.06.2024; BioMed Central; BMC
• Subjects: Antibodies; Apoptosis; Biomimetics; Breast cancer; Cancer; Cancer therapies; Cell membranes; Cell proliferation; Chemotherapy; Controlled release; Drug resistance; ErbB-2 protein; Ethylenediaminetetraacetic acid; Flow cytometry; Health aspects; HER2-positive breast cancer; Immunofluorescence; Kinases; Light scattering; Lipids; Liposome; Liposomes; Medical research; Oncology, Experimental; Particle size; Polyacrylamide; Proteins; Pyrotinib; SK-BR-3 cell membranes; Targeted therapy; Transmission electron microscopy; Trastuzumab; Tumor cells; Western blotting; Womens health; Canada; China; Germany; United Kingdom > UK; Beijing China

In this study, we prepared a bionic nanosystem of trastuzumab-functionalized SK-BR-3 cell membrane hybrid liposome-coated pyrotinib (Ptb-M-Lip-Her) for the treatment of HER2-positive breast cancer. Transmission electron microscopy, dynamic light scattering, polyacrylamide gel electrophoresis (SDS-PA...